Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH 4–10), engineered for stability so it can act in the brain without the hormonal effects of the parent molecule. Developed in Russia, it is studied as a neuroprotective and nootropic peptide.
Mechanism under investigation
Research links Semax to increased expression of neurotrophic factors — BDNF and NGF — and to modulation of the dopaminergic and serotonergic systems. In models of cerebral ischemia it shows neuroprotective activity, which is the focus of much of the preclinical work.
Research applications
- Cognition, attention, and memory in behavioral models.
- Neuroprotection in stroke and hypoxia models.
- Neurotrophic signaling (BDNF/NGF) in neuronal cultures.
Clinical outlook
Semax is notable for already being in real clinical use: in Russia it is a registered pharmaceutical applied in neurological practice, including ischemic-stroke and cognitive-support settings. Much of its human evidence is published in the Russian-language literature, and internationally registered trials remain limited — so a major opportunity for the field is to reproduce and extend those findings in Western clinical research. Interest in its neurotrophic mechanism is growing accordingly.
References
- Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice
- Functional Connectomic Approach to Studying Selank and Semax Effects
- The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease
- The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis
- Semax, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation and Amyloid Formation in Artificial Membrane Models
